ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 0419

Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
Abstract Number: 0936

Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE
Abstract Number: 0521

Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression
Abstract Number: 2321

Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
Abstract Number: 0349

Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort
Abstract Number: 1402

Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Abstract Number: 2660

Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
Abstract Number: 1426

Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis
Abstract Number: 2691

Understanding the Impact of Overweight and Obesity on Treatment Response in Psoriatic Arthritis: Results from a Longitudinal Cohort Study
Abstract Number: 0068

Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
Abstract Number: 2647

Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features
Abstract Number: 2490

Unmasking Mortality Risk: The Impact of Systemic Sclerosis in Stress-Induced Cardiomyopathy
Abstract Number: 1859

Unraveling Disparities in Systemic Lupus Erythematosus-Related Mortality Among U.S. Adults (≥25 Years) with Malignancy: A Longitudinal Analysis of Gender, Race, and Geographic Inequities Using CDC WONDER (1999–2020)”
Abstract Number: 2489

Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum
Abstract Number: 2497

Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Abstract Number: 0971

Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3
Abstract Number: 0071

Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.
Abstract Number: 1088

Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Abstract Number: 0543

Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients
Abstract Number: 2474

Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected
Abstract Number: 1529

Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
Abstract Number: 2304

Updates in the local treatments in Primary Sjögren’s Syndrome “Efficacy and Safety”
Abstract Number: 1345

Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study
Abstract Number: 1480

Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
Abstract Number: 1750

Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Abstract Number: 0851

Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
Abstract Number: 0302

Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Abstract Number: 1356

Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Abstract Number: 0686

Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Abstract Number: 0234

Use of Corneal Confocal Microscopy to Assess Small Fiber Neuropathy in Patients with Sarcoidosis
Abstract Number: 1598

Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
Abstract Number: 1618

Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
Abstract Number: 2301

Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Abstract Number: 0247

Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Abstract Number: 1355

Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Abstract Number: 1261

Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA
Abstract Number: 1578

Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
Abstract Number: 0505

Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect
Abstract Number: 2446

Use of Voclosporin in Pediatric Patients: A Summary of Available Data from Post-marketing Reports
Abstract Number: 1561

Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
Abstract Number: 2566

Using Abdominal CT-Derived Bone Mineral Density and Psoas Volume for Opportunistic Osteoporosis Screening and Fracture Risk Assessment
Abstract Number: 0794

Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
Abstract Number: 2174

Using Natural Language Processing to Identify Character Strengths in Rheumatology Fellowship Candidate Applications: A Feasibility Study
Abstract Number: 0994

UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
Abstract Number: 1979

Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
Abstract Number: 0716

Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis
Abstract Number: 0195

Utility of Repeat ANA Testing
Abstract Number: 0827

Utilization of American College of Rheumatology Vaccination Guidelines in Clinic: A Needs Assessment in an Internal Medicine Residency Program
Abstract Number: 2046

Utilization of the All of Us Research Program to Study the Impact of Genetic Background on Autoinflammatory Diseases
Abstract Number: 1978

Utilizing a Gap to Target Function in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry Dashboard of Quality Measures
Abstract Number: 2194

Utilizing Case-Based Learning to Teach the Teacher and Improve Health Insurance Literacy
Abstract Number: 0916

UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].